Nutriband's (NTRB) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Nutriband's stock is rated as a "sell (D-)" by Weiss Ratings, with recent downgrades from other analysts including Wall Street Zen and Zacks Research.
• The company reported a significant earnings miss, with an EPS of ($2.12), falling short of estimates by ($1.95).
• Institutional investors hold 19.70% of Nutriband's stock, with the latest addition being a new stake acquired by Consolidated Portfolio Review Corp valued at approximately $81,000.

Nutriband (NASDAQ:NTRB - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Nutriband from a "hold" rating to a "sell" rating in a research report on Friday, September 26th. Zacks Research lowered Nutriband from a "hold" rating to a "strong sell" rating in a report on Tuesday, September 16th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Reduce" and a consensus price target of $13.00.

Nutriband Stock Performance

Shares of NTRB opened at $8.50 on Wednesday. The company has a current ratio of 4.78, a quick ratio of 4.70 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $102.26 million, a price-to-earnings ratio of -2.96 and a beta of 1.13. The stock has a 50 day moving average of $6.85 and a 200 day moving average of $6.79. Nutriband has a 12 month low of $3.72 and a 12 month high of $11.78.

Nutriband (NASDAQ:NTRB - Get Free Report) last issued its quarterly earnings results on Tuesday, September 9th. The company reported ($2.12) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.95). The business had revenue of $0.62 million for the quarter, compared to analysts' expectations of $0.71 million. Nutriband had a negative net margin of 398.29% and a negative return on equity of 85.40%. As a group, sell-side analysts forecast that Nutriband will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Nutriband

An institutional investor recently bought a new position in Nutriband stock. Consolidated Portfolio Review Corp acquired a new stake in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,350 shares of the company's stock, valued at approximately $81,000. Consolidated Portfolio Review Corp owned 0.09% of Nutriband as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 19.70% of the company's stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.